Autoimmune Lebererkrankungen
Standard
Autoimmune Lebererkrankungen : Diagnostik und Therapie. / Bayer, E M; Schramm, C; Kanzler, S; Lohse, A W.
in: Z GASTROENTEROL, Jahrgang 42, Nr. 1, 01.2004, S. 19-30.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autoimmune Lebererkrankungen
T2 - Diagnostik und Therapie
AU - Bayer, E M
AU - Schramm, C
AU - Kanzler, S
AU - Lohse, A W
PY - 2004/1
Y1 - 2004/1
N2 - Autoimmune Hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndromes of these three disease entities are regarded as autoimmune liver diseases. These conditions are important differential diagnoses of elevated liver function tests as about 10 % of liver transplantations in Europe and North America are for these indications. The diagnosis is often difficult but can be facilitated by sequential measurement of relevant autoantibodies, exclusion of other liver disease, ultrasound, ERCP and liver histology. In AIH immunosuppressive therapy has been shown to prevent or stop the development of cirrhosis and improve the prognosis of the patients decisively. In other autoimmune liver diseases this evidence is missing making individual therapeutic decisions necessary. Ursodesoxycholic acid (UDCA) seems to slow disease progression in particular in early stages of PBC.
AB - Autoimmune Hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndromes of these three disease entities are regarded as autoimmune liver diseases. These conditions are important differential diagnoses of elevated liver function tests as about 10 % of liver transplantations in Europe and North America are for these indications. The diagnosis is often difficult but can be facilitated by sequential measurement of relevant autoantibodies, exclusion of other liver disease, ultrasound, ERCP and liver histology. In AIH immunosuppressive therapy has been shown to prevent or stop the development of cirrhosis and improve the prognosis of the patients decisively. In other autoimmune liver diseases this evidence is missing making individual therapeutic decisions necessary. Ursodesoxycholic acid (UDCA) seems to slow disease progression in particular in early stages of PBC.
KW - Adult
KW - Autoantibodies
KW - Autoimmune Diseases
KW - Azathioprine
KW - Biopsy
KW - Child
KW - Cholagogues and Choleretics
KW - Cholangiopancreatography, Endoscopic Retrograde
KW - Cholangitis, Sclerosing
KW - Diagnosis, Differential
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Hepatitis, Autoimmune
KW - Humans
KW - Immunoassay
KW - Immunosuppression
KW - Immunosuppressive Agents
KW - Liver
KW - Liver Cirrhosis, Biliary
KW - Liver Diseases
KW - Liver Function Tests
KW - Liver Transplantation
KW - Male
KW - Middle Aged
KW - Mycophenolic Acid
KW - Prognosis
KW - Ultrasonography
KW - Ursodeoxycholic Acid
KW - Comparative Study
KW - Journal Article
KW - Review
U2 - 10.1055/s-2004-812686
DO - 10.1055/s-2004-812686
M3 - SCORING: Review
C2 - 14997400
VL - 42
SP - 19
EP - 30
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 1
ER -